Concurrent chemoradiotherapy with cyclophosphamide, pirarubicin, and cisplatin for patients with locally advanced salivary gland carcinoma
Authors:
- 1 January 2006
- journal article
- research article
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 126 (12) , 1309-1314
Abstract
Conclusion. This concurrent chemoradiotherapy with CPA, THP, and CDDP showed major antitumor activity with manageable toxicity as treatment of advanced salivary gland carcinoma patients. The high response rate (RR) justifies further evaluation of this chemoradiotherapy combination. Objectives. The aim of this study was to evaluate the efficacy and toxicity of a concurrent chemoradiotherapy using cyclophosphamide (CPA), pirarubicin (THP), and cisplatin (CDDP) in patients with locally advanced salivary gland carcinoma. Patients and methods. Seventeen patients with previously untreated stage III–IV salivary gland carcinoma were entered in this trial between January 2000 and September 2005. Chemotherapy consisted of CPA 400 mg/m2 on day 1, THP 40 mg/m2 by 6-h infusion on day 1, and CDDP 60 mg/m2 by 2-h infusion on day 1. Radiotherapy (2.0 Gy/fraction/day, mean total dose: 67.2 Gy (64.0–72.0 Gy)) administered 5 days per week, was targeted to begin on day 1. Results. The RR was 76% (13/17) and the pathological complete response (CR) was 24% (4/17). The primary site CR was 29% (5/17) and metastatic lymph node CR was 33% (4/12). The 5-year survival rate was 70%. Neutropenia, leukocytopenia and mucositis were common adverse effects, but all 17 patients were assessable for toxicity.Keywords
This publication has 25 references indexed in Scilit:
- Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neckInternational Journal of Clinical Oncology, 2004
- Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neckJournal of Cancer Research and Clinical Oncology, 1993
- Primary Parotid Malignancies: A Clinical and Pathologic ReviewJAMA Otolaryngology–Head & Neck Surgery, 1991
- Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1990
- Carcinoma of Major Salivary Glands: Recent TrendsJAMA Otolaryngology–Head & Neck Surgery, 1989
- Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland originCancer, 1987
- 5-Fluorouracil, Cyclophosphamide, and Vincristine for Adenoid Cystic Carcinoma of the Head and NeckCancer, 1987
- Chemotherapy for salivary gland cancerOtolaryngology–Head and Neck Surgery, 1986
- Salivary neoplasms: Overview of a 35‐year experience with 2,807 patientsHead & Neck Surgery, 1986
- Cyclophosphamide, adriamycin, and cisdiamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancerCancer, 1983